



PRESS RELEASE NOVEMBER 8<sup>th</sup>, 2013

## MOBERG PHARMA'S NOMINATION COMMITTEE APPOINTED

In accordance with the resolution of the Annual General Meeting on April 23, 2013, the Chairman of the Board has contacted the company's three largest shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.

Moberg Pharma's Nomination Committee ahead of the 2014 Annual General Meeting comprises:

- Mats Petterson, Chairman of the Board
- Per-Olof Edin, appointed by Östersjöstiftelsen
- Håkan Åström, appointed by SIX SIS AG
- Henrik Blomquist, appointed by Bure Equity AB (Publ)

Per-Olof Edin has been appointed Chairman of the Nomination Committee. Together, the Nomination Committee represents 43.5 percent of the shares in Moberg Pharma as of September 30, 2013.

The Nomination Committee shall submit proposals for resolution by the 2014 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

The 2014 Annual General Meeting will be held in Stockholm on May 13.

Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to [info@mobergpharma.se](mailto:info@mobergpharma.se) by 31 December 2013.

**For further information, please contact:**

Peter Wolpert, CEO

Telephone: +46 8 522 307 00; Mobile: +46 707 35 71 35; E-mail: [peter.wolpert@mobergpharma.se](mailto:peter.wolpert@mobergpharma.se)

Peter Östling, IR

Mobile: +46 76 314 09 78; Email: [peter.ostling@mobergpharma.se](mailto:peter.ostling@mobergpharma.se)

**About Moberg Pharma AB**

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with its own sales organization in the US and sales through distributors in more than 40 countries. The company's product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal<sup>®</sup>, Jointflex<sup>®</sup>, Kerasal Nail<sup>®</sup> and Kaprolac<sup>®</sup>. Kerasal Nail<sup>®</sup> (Nalox<sup>™</sup> in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company's share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: [www.mobergpharma.com](http://www.mobergpharma.com).